Production (Stage)
Beam Therapeutics Inc.
BEAM
$16.83
-$0.41-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.81% | -90.49% | -17.01% | -41.48% | -69.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.81% | -90.49% | -17.01% | -41.48% | -69.39% |
| Cost of Revenue | -10.84% | -27.58% | -5.79% | -10.83% | -82.29% |
| Gross Profit | 19.27% | -140.53% | 3.46% | 2.87% | 86.43% |
| SG&A Expenses | 4.55% | -33.74% | 4.35% | 20.16% | 13.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.64% | -29.03% | -3.74% | -4.58% | -9.42% |
| Operating Income | -14.55% | -175.30% | 1.63% | -2.69% | -5.26% |
| Income Before Tax | -10.74% | -162.67% | -0.60% | -9.95% | -2.29% |
| Income Tax Expenses | -- | -100.00% | -- | -- | -- |
| Earnings from Continuing Operations | -10.74% | -163.27% | -0.60% | -10.00% | -2.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.74% | -163.27% | -0.60% | -10.00% | -2.29% |
| EBIT | -14.55% | -175.30% | 1.63% | -2.69% | -5.26% |
| EBITDA | -15.26% | -168.44% | 1.99% | -2.04% | -4.69% |
| EPS Basic | -2.85% | -161.77% | 3.53% | -2.01% | 9.51% |
| Normalized Basic EPS | -4.55% | -160.91% | 0.19% | 13.25% | -1.01% |
| EPS Diluted | -2.85% | -163.44% | 3.53% | -2.01% | 9.51% |
| Normalized Diluted EPS | -4.55% | -162.31% | 0.19% | 13.25% | -1.01% |
| Average Basic Shares Outstanding | 7.68% | 2.43% | 4.28% | 7.83% | 13.04% |
| Average Diluted Shares Outstanding | 7.68% | 0.15% | 4.28% | 7.83% | 13.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |